Clinical Research Directory
Browse clinical research sites, groups, and studies.
Obstructive Sleep Apnea (OSA) and Sex-Specific Responses to N-acetylcysteine (NAC)
Sponsor: NYU Langone Health
Summary
This is a randomized controlled trial (RCT) of 4 weeks of study supplement N-acetylcysteine (NAC) versus placebo in persons with significant obstructive sleep apnea (OSA) who are receiving positive airway pressure therapy (PAP), the standard of care therapy. The purpose of the study is to determine if NAC is associated with sex-specific changes in overnight oxidative stress, inflammation, as well as endothelial dysfunction in persons with OSA.
Official title: Basis of Sex-specific Therapeutic Responses to Obstructive Sleep Apnea (OSA): a Trial of N-acetylcysteine (NAC) in Obstructive Sleep Apnea (OSA)
Key Details
Gender
All
Age Range
55 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
14
Start Date
2024-05-07
Completion Date
2026-04
Last Updated
2026-03-04
Healthy Volunteers
No
Conditions
Interventions
N-acetylcysteine (NAC)
Participants will take two NAC 600mg capsules daily for four weeks.
Placebo
Participants will take two placebo 600mg capsules daily for four weeks.
Positive Airway Pressure (PAP) Therapy
All participants will receive PAP therapy per standard of care for OSA.
Locations (1)
NYU Langone Health
New York, New York, United States